HIPPOCRATES has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 101007757. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The information reflects only the author's view and the IMI JU is not responsible for any use that may be made of the information it contains.
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, biopharmaceutical and other companies, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
For further information: www.imi.europa.eu